Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 2/2016

01-02-2016 | Erratum

Erratum to: Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study)

Authors: Pere Gascón, Matti Aapro, Heinz Ludwig, Carsten Bokemeyer, Mario Boccadoro, Matthew Turner, Kris Denhaerynck, Karen MacDonald, Ivo Abraham

Published in: Supportive Care in Cancer | Issue 2/2016

Login to get access

Excerpt

Erratum to: Support Care Cancer …
Metadata
Title
Erratum to: Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study)
Authors
Pere Gascón
Matti Aapro
Heinz Ludwig
Carsten Bokemeyer
Mario Boccadoro
Matthew Turner
Kris Denhaerynck
Karen MacDonald
Ivo Abraham
Publication date
01-02-2016
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 2/2016
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-015-2991-3

Other articles of this Issue 2/2016

Supportive Care in Cancer 2/2016 Go to the issue

Original Article

Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study

Original Article

Risk factors for bone pain among patients with cancer receiving myelosuppressive chemotherapy and pegfilgrastim

Original Article

Translation of Supportive Care Needs Survey Short Form 34 (SCNS-SF34) into Italian and cultural validation study

Original Article

Improving cancer patients’ knowledge about totally implantable access port: a randomized controlled trial

Original Article

Perceived barriers and benefits to physical activity in colorectal cancer patients

Original Article

Negative and positive life changes following treatment completion: Chinese breast cancer survivors’ perspectives
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits